Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum BioPharma Announces Closing of Private Placement & Provides Corporate UpdateToronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (\"Quantum BioPharma\" or the \"Company\"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce that, further to its news release on October 29, 2025 it has closed a non-brokered private placement and issued 30 class A multiple voting shares (\"Class A Multiple Voting Shares\") of the Company at a price of $25 Per Class A Multiple Voting Shares for gross proceeds of $750 (the \"Offering\"). The Offering All securities issued pursuant to the Offering are subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws of Canada. The Company intends to use the proceeds of the Offering for general working capital purposes. MI 61-101 DisclosureXorax Family Trust (\"Xorax\"), a trust of which Zeeshan Saeed (\"Mr. Saeed\"), the Chief Executive Officer and Co-Chairman of the Company is a beneficiary, and Fortius Research and Trading Corp. (\"Fortius\"), a corporation of which Anthony Durkacz (\"Mr. Durkacz\"), a director of the Company, purchased all the Class A Multiple Voting Shares issued pursuant to the Offering. The participation by such insiders is considered a \"related-party transaction\" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (\"MI 61-101\"). The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in respectively, sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the Offering as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involved the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61-101).The Company has filed a material change report more than 21 days before the expected closing...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B